Chronic kidney disease(CKD) is a chronic renal insufficiency syndrome characterized by the loss of nephrons，inflammatory responses，activation of myofibroblasts，and extracellular matrix deposition.CKD has a high prevalence，affecting approximately 10% to 13% of the global population，making it a significant public health issue worldwide.Huangkui Capsules，a Chinese patent medicine approved by the National Medical Products Administration，are composed of herbal drug Abelmoschi Corolla and are known for their high safety profile.Clinically，they are commonly used to treat kidney-related diseases.Studies have shown that Huangkui Capsules can treat CKD by improving immune function，inhibiting inflammatory responses，alleviating renal fibrosis，and reducing damage to renal tubular epithelial cells.However，there is still a lack of clinical data on the efficacy of Huangkui Capsules in improving CKD and a need for further research into their pharmacological mechanisms.